Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its co-developed FH-2001 in combination with HanSiZhuang (serplulimab, HLX10) for the treatment of advanced solid tumors.
FH-2001 is a small molecule modulator/inhibitor that targets programmed-death ligand 1 (PD-L1) and fibroblast growth factor receptor (FGFR), and is currently undergoing a Phase Ib/II clinical study in China. HanSiZhuang, an anti-programmed death-1 (PD-1) inhibitor, was first approved for marketing in China in March 2022 and has since garnered four indication approvals. It is indicated for use in MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC), extensive stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC).- Flcube.com
